Cipla Share Price
(CIPLA)
Check the latest share price of Cipla, details on performance, fundamentals, analyst ratings, peer comparison, financials, company news, analysis, and shareholding pattern for informed investing decisions.
as on 04:01PM, 02 May 2025
NSE
Cipla Performance
Get real-time share price information, day’s high and low, historical returns and market stats.
Day's Low
Day's High
₹1,513.5Day's Price Range₹1,552.552 Week's Low
52 Week's High
₹1,317.2552-Week Price Range₹1,702.05
| Returns % | |
| 1 Month Return | + 2 % |
| 3 Month Return | + 7.4 % |
| 1 Year Return | + 7.08 % |
| Market Stats | |
| Previous Close | ₹1,550.10 |
| Open | ₹1,537.50 |
| Volume | 20.20L |
| Upper Circuit | ₹1,705.10 |
| Lower Circuit | ₹1,395.10 |
| Market Cap | ₹1,23,213.62Cr |
Cipla Fundamentals & Key Indicators
Check the fundamental ratios and key indicators of the company like P/E, P/B, PEG, Dividend yield etc.
Market Cap
₹1,23,213.62 Cr
Return on Equity (ROE)
15.5
PE Ratio (TTM)
24.69
Return on capital employed (ROCE)
20.1
Beta (LTM)
0.54
P/B Ratio
4.31
Dividend Yield
0.87
PEG Ratio
1.56
EPS (TTM)
51.47
Sector
Pharmaceuticals
Technical Analysis
Bullish
View Technical Analysis
How to invest in Cipla
Investing in Cipla is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Cipla or CIPLA on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Cipla or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Cipla with just a few clicks!
Cipla Valuation
Track how the P/E of Cipla has moved over time to understand valuation trends.
Cipla in the last 5 years
Lowest (18.11x)
March 19, 2020
Today (24.69x)
May 2, 2025
Industry (54.34x)
May 2, 2025
Highest (42.80x)
January 23, 2018
Today’s Price to Earnings Ratio: 24.69x
Analysts Recommendation on Cipla
Get updated buy, sell, and hold recommendations by analysts on Cipla.
based on 37 analysts
64.86%
Buy
21.62%
Hold
13.51%
Sell
64.86% of analysts recommend a 'BUY' rating for Cipla. Average target price of ₹1640.92
Source: S&P Global Market Intelligence
Analysts Forecast on Cipla
Get share price movements and forecasts by analysts on Cipla.
Cipla price forecast by 37 analysts
Upside of7.56%
High
₹1875
Target
₹1640.92
Low
₹1204
Cipla target price ₹1640.92, a slight upside of 7.56% compared to current price of ₹1525.6. According to 37 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Cipla revenue growth forecast
Expected growth rate Q1, FY2027:24.62%
Forecast
Actual
Including amortisation and stock based compensations
Cipla EPS growth forecast
EPS estimate Q1, FY2027:30.42%
Forecast
Actual
Source: S&P Global Market Intelligence
Cipla Financials
Get the annual and quarterly financial summary of Cipla, including revenue, profit, loss and more.
Cipla Index Inclusions
Cipla Earnings and Dividends
View detailed summary of the earnings and dividend history of Cipla.
Cipla Ltd Earnings Results
Cipla Ltd’s net profit jumped 48.74% since last year same period to ₹1,570.51Cr in the Q3 2024-2025. On a quarterly growth basis, Cipla Ltd has generated 20.57% jump in its net profits since last 3-months.
Read More about Earnings ResultsCipla Ltd Dividends May,2024
In the quarter ending March 2024, Cipla Ltd has declared dividend of ₹13 - translating a dividend yield of 1.41%.
Read More about Dividends
Cipla Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Cipla.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 29.13% | 0.00 | |
| Foreign Institutions | 26.22% | 0.00 | |
| Mutual Funds | 20.47% | 0.00 | |
| Retail Investors | 16.33% | 0.00 | |
| Others | 7.85% | 0.00 |
Cipla vs Peers
Compare market cap, revenue, PE, and other key metrics of Cipla with its industry peers.
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹1,23,213.62 Cr | 29.87% | 0.50 | ₹4,155 Cr | ₹25,774 Cr | |
| HOLD | ₹1,62,042.02 Cr | 33.38% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,10,165.81 Cr | 34.8% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹38,287.13 Cr | -2.18% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹23,123.56 Cr | -4.57% | 0.50 | ₹772 Cr | ₹5,664 Cr |
Cipla News & Key Events
Latest news and events at one place to help you take investing decisions in Cipla.
Cipla Reports Strong Growth and Future Prospects - 03 May, 2025
Cipla's consolidated sales rose 13% to ₹257.7 billion, driven by US performance and domestic growth. Despite a slowdown in 9MFY25, net profit increased by 27%. The company focuses on expanding its ANDA pipeline and aims to lead in inhaled medicines, leveraging AI for research. Cipla trades at a lower P/E ratio compared to its historical median, indicating potential value.Cipla Shows Improvement in Market Shares - 02 May, 2025
Nomura maintains a Buy rating on Cipla, noting a recovery in Albuterol's market share to 19% in March 2025. The company also reported a slight improvement in sales and volume market share for Lanreotide injection, expecting supply restoration to pre-disruption levels by Q1 FY26.Cipla Plans US Expansion with Strong Pipeline - 27 Apr, 2025
Cipla aims to enhance its US presence through manufacturing expansion and strategic partnerships. The company has a robust pipeline, including key respiratory drug filings, and significant revenue contributions from the US market.Cipla Expands Services and Reports Strong Earnings - 21 Apr, 2025
Cipla's Goa facility received a VAI classification from the US FDA, while the company reported a significant profit increase in Q3 FY25. Additionally, Cipla Foundation expanded palliative care services in Pune, aiding over 900 cancer patients.Cipla's Medispray Facility Receives VAI Classification - 18 Apr, 2025
Cipla Ltd announced that its Medispray Laboratories facility in Goa received a Voluntary Action Indicated (VAI) classification from the USFDA, indicating non-critical issues. The company views this as part of its commitment to good governance practices.Nomura Reaffirms Buy Rating on Cipla with Target Price - 14 Apr, 2025
Nomura maintains a 'Buy' rating on Cipla Ltd, setting a target price of Rs 1,780 by March 2026. The approval of gAbraxane by the USFDA enhances Cipla's market visibility, with expected revenues of $18 million and $56 million for FY26 and FY27, respectively. Despite competition, Cipla is anticipated to capture significant market share.Cipla Secures USFDA Approval for Generic Cancer Drug - 11 Apr, 2025
Cipla Limited received final USFDA approval for its generic version of Abraxane, enhancing its oncology portfolio. The product is expected to launch in the first half of FY 2025-26, leading to a 5% share price increase.Cipla Secures FDA Approval and Announces Earnings Date - 10 Apr, 2025
Cipla has received USFDA approval for Lanreotide injection, marking a significant milestone for its US business. Additionally, the company announced its Q4 FY2025 earnings release date and potential dividend on May 13, 2025.Cipla Reports Strong Q3 FY25 Financial Results - 08 Apr, 2025
Cipla Ltd announced a revenue of Rs 7,073 crore and a net profit of Rs 1,575 crore for Q3 FY25, reflecting significant growth compared to the previous year.Cipla Faces Pressure Amid Pharma Index Decline - 07 Apr, 2025
Cipla's stock faced downward pressure as its share price contributed to the NSE Nifty Pharma index reaching its lowest level in over 10 months.Cipla Shares Plummet Amid Tariff Concerns - 04 Apr, 2025
Cipla Ltd's shares fell 6.08% due to concerns over potential U.S. pharmaceutical tariffs announced by President Trump, impacting investor sentiment significantly.
Insights on Cipla Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 3 months, CIPLA stock has moved up by 7.4%
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 20.42% to 20.47% in Mar 2025 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 4 quarters, 939.04 Cr → 1.57K Cr (in ₹), with an average increase of 15.6% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 6.41K Cr → 7.29K Cr (in ₹), with an average increase of 4.2% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 29.13% of holdings in Mar 2025 quarter
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 141.8% return, outperforming this stock by 82.5%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 54.5% return, outperforming this stock by 47.4%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 16.41% to 16.33% in Mar 2025 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 26.60% to 26.22% in Mar 2025 quarter
About Cipla
Cipla's operations include manufacturing, marketing, and distribution of pharmaceuticals, biotechnology, and consumer healthcare products. Its top products include respiratory, anti-infectives, cardiovascular, and oncology drugs. Popular brands include Asthalin, Cipcal, Cifran, and Erythromycin. Cipla also manufactures nutraceuticals, herbal products, and over-the-counter medicines.
Revenue: ₹6,961.60Cr as on December 2024 (Q4 24)
Net Profit: ₹1,583.72Cr as on December 2024 (Q4 24)
Listing date: 03 Nov, 1994
Chairperson Name: Y K Hamied
| Organisation | Cipla Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Indian Mutual Funds that own Cipla
Check out the Mutual Funds with significant holdings in Cipla.
FAQs
What is Cipla Ltd price today?
Cipla Ltd share price today stands at ₹1525.6, Open: ₹1537.5, Previous Close: ₹1550.1, High: ₹1552.5, Low: ₹1513.5, 52 Week High: ₹1702.05, 52 Week Low: ₹1317.25.
How to Buy Cipla Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Cipla Ltd shares
What are today's traded volumes of Cipla Ltd?
Today's traded volume of Cipla Ltd(CIPLA) is 20.20L.
What is today's market capitalisation of Cipla Ltd?
Today's market capitalisation of Cipla Ltd(CIPLA) is ₹1,23,213.62 Cr.
What is the 52 Week High and Low Range of Cipla Ltd?
How much percentage Cipla Ltd is down from its 52 Week High?
Cipla Ltd (CIPLA) share price is ₹1525.6. It is down -10.37% from its 52 Week High price of ₹1702.05
How much percentage Cipla Ltd is up from its 52 Week low?
Cipla Ltd (CIPLA) share price is ₹1525.6. It is up 15.82% from its 52 Week Low price of ₹1317.25